Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 601–700 of 1,001
Gomez, C., Bai, L., Zhang, J., Nikolovska-Coleska, Z., Chen, J., Yi, H., & Wang, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.091 · Cited by 26
Munde, M. M., Poon, G. M. K., & Wilson, W. D. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.02.010 · Cited by 31
“In addition, small molecules that could modulate transcription factor–DNA interfaces would allow for the chemical control of gene networks.(25,45) With the explosion of information on the regulatory mechanisms for gene expression, including regulation circuits from noncoding DNA regions as recently shown by the ENCODE…”
Singh, S., & Bhat, M. K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.037 · Cited by 26
SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis
Specht, S. M., Isse, K., Nozaki, I., Lunz, J. G., & Demetris, A. J. (2013) · Clinical & Experimental Metastasis · doi:10.1007/s10585-013-9589-2 · Cited by 25
“STAT3 activation results in tyrosine phosphorylation and dimerization of two STAT molecules through their SH2 domains [12].”
Zacksenhaus, E., Liu, J.-K., Jiang, Z., Yao, Y., Xia, L., Shrestha, M., & Ben‐David, Y. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.003 · Cited by 30
Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition
Toure, M. A., & Koehler, A. N. (2023) · Biochemistry · doi:10.1021/acs.biochem.2c00609 · Cited by 25
A systems biology approach to the global analysis of transcription factors in colorectal cancer
Pradhan, M. P., Prasad, N. K., & Palakal, M. J. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-331 · Cited by 26
“For example STAT3 , NF-kB , and c-Jun are oncogenic in CRC [38].”
BackgroundGuan, Y., Li, Z., & Liu, J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.044 · Cited by 28
CSI–FID: High throughput label-free detection of DNA binding molecules
Hauschild, K. E., Stover, J. S., Boger, D. L., & Ansari, A. Z. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.097 · Cited by 26
Influence of conformationally restricted pyrimidines on the activity of 10–23 DNAzymes
Robaldo, L., Izzo, F., Dellafiore, M. A., Proietti, C. J., Elizalde, P. V., Montserrat, J. M., & Iribarren, A. M. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.02.047 · Cited by 25
Elumalai, N., Berg, A., Rubner, S., & Berg, T. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00817 · Cited by 25
Widen, J. C., Kempema, A., Baur, J. W., Skopec, H. M., Edwards, J. T., Brown, T. J., Brown, D. A., Meece, F. A., & Harki, D. A. (2018) · ChemMedChem · doi:10.1002/cmdc.201700752 · Cited by 25
Effects of 6-Thioguanine and S6-Methylthioguanine on Transcription in Vitro and in Human Cells
You, C., Dai, X., Yuan, B., & Wang, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.418681 · Cited by 26
“In this context, somedrug-inducedDNAdamage may inhibit the initiation of RNA synthesis by altering the binding of some transcription factors to DNA, whereas others may act as a physical impediment to transcription elongation by RNA polymerase (RNAP) (26, 27, 31).”
BackgroundPolyamides as Artificial Transcription Factors: Novel Tools for Molecular Medicine?
Schmitz, K., & Schepers, U. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200301745 · Cited by 28
Weaver, A. M., & Silva, C. M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0418 · Cited by 28
Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells.
Acuña, U. M., Wittwer, J. A., Ayers, S., Pearce, C. J., Oberlies, N. H., & Blanco, E. J. C. D. (2012) · PubMed · Cited by 24
Development of a peptide-based inducer of protein degradation targeting NOTCH1
Ohoka, N., Misawa, T., Kurihara, M., Demizu, Y., & Naito, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.011 · Cited by 27
Lee, S. M., Kim, N.-H., Lee, S., Kim, N.-H., Heo, J., Rho, J., & Jeong, E. J. (2019) · Molecules · doi:10.3390/molecules24183394 · Cited by 24
“on the phosphorylation-induced degradation of IκB-α, an inhibitor of NF-κB [8,24].”
BackgroundInfluentialLiu, S., Yu, J., Creeden, J. F., Sutton, J. M., Markowiak, S. F., Sanchez, R., Nemunaitis, J. J., Nestor‐Kalinoski, A. L., Zhang, J., Damoiseaux, R. D., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.002 · Cited by 28
“PDX1 regulates proliferation and invasion of human PDAC cell lines and mouse models [32, 42, 49-52].”
BackgroundMolecular Action of Polyphenols in Leukaemia and Their Therapeutic Potential
Alaswad, H. A., Mahbub, A. A., Maitre, C. L. L., & Jordan, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063085 · Cited by 28
Drugging Fuzzy Complexes in Transcription
Su, B. G., & Henley, M. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.795743 · Cited by 28
“As a consequence of their disorder, TFs are largely considered an “undruggable” protein class (Darnell, 2002; Bushweller, 2019; Henley and Koehler, 2021).”
BackgroundThe importance of oncogenic transcription factors for oral cancer pathogenesis and treatment.
Yedida, G., Nagini, S., & Mishra, R. (2013) · Oral surgery, oral medicine, oral pathology and oral radiology · doi:10.1016/j.oooo.2013.02.010 · Cited by 24
Computational study on mechanism of G-quartet oligonucleotide T40214 selectively targeting Stat3
Zhu, Q., & Jing, N. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9147-6 · Cited by 26
Expression of YY1 correlates with progression and metastasis in esophageal squamous cell carcinomas
Luo, J., Cao, L., Jiang, X. J., Dai, K., Zhang, S., Ge, X., Zhou, X., & Lu, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66667 · Cited by 24
“6 Massive evidence indicates that transcription factors act as important players in human cancer development and progression, and it has been shown that the dysregulation of many transcription factors, such as Oct3/4, Sox2, KLF4, and EGR-1, is involved in the occurrence and development of…”
Towards the emerging crosstalk: ERBB family and steroid hormones
D’Uva, G., & Lauriola, M. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.11.004 · Cited by 25
He, N., Feng, G., Yang, L., Xu, Y., Xie, X., Wang, H., Wang, Y., Ou, L., Pei, X., Liu, N., et al. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0360-x · Cited by 26
Mixed up minor groove binders: Convincing A·T specific compounds to recognize a G·C base pair
Paul, A., Nanjunda, R. K., Kumar, A., Laughlin, S., Nhili, R., Depauw, S., Deuser, S. S., Chai, Y., Chaudhary, A. S., David‐Cordonnier, M., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.005 · Cited by 28
Acuña, U. M., Mo, S., Zi, J., Orjala, J., & de Blanco, E. J. C. (2018) · Anticancer Research · doi:10.21873/anticanres.12595 · Cited by 24
Innate extracellular vesicles from melanoma patients suppress β-catenin in tumor cells by miRNA-34a
Lee, J., Dindorf, J., Eberhardt, M., Lai, X., Ostalecki, C., Koliha, N., Gross, S., Blume, K., Bruns, H., Wild, S., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800205 · Cited by 25
Recent advance in the sensing of biomarker transcription factors
Li, B., Xie, S., Xia, A., Suo, T., Huang, H., Zhang, X., Chen, Y., & Zhou, X. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.116039 · Cited by 24
Paz, K., Socci, N. D., van Nimwegen, E., Viale, A. J., & Darnell, J. E., Jr. (2004) · Oncogene · doi:10.1038/sj.onc.1207803 · Cited by 27
“Persistent and aberrant STAT3 activation has been detected in many human cancers (Turkson et al., 1998; Darnell, 2002).”
BackgroundComplex-based analysis of dysregulated cellular processes in cancer
Srihari, S., Madhamshettiwar, P. B., Song, S., Liu, C., Simpson, P. T., Khanna, K. K., & Ragan, M. A. (2014) · BMC Systems Biology · doi:10.1186/1752-0509-8-s4-s1 · Cited by 29
“Darnell [8] also discussed the signalling pathways of these TFs (including Wnt-b-catenin, Notch and Hedgehog signalling) as potential drug targets in cancer.”
BackgroundSTAT3 Inhibitors in Cancer: A Comprehensive Update
Bharadwaj, U., Kasembeli, M. M., & Tweardy, D. J. (2016) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-42949-6_5 · Cited by 26
Melatonin derivatives combat with inflammation-related cancer by targeting the Main Culprit STAT3
Ma, S., Zhu, L., Fan, X., Luo, T., Liu, D., Liang, Z., Hu, X., Shi, T., Tan, W., & Wang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113027 · Cited by 24
Research progress of STAT3-based dual inhibitors for cancer therapy
Yang, X.-J., Xu, L., Yang, L., & Xu, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117382 · Cited by 25
Indirect readout in drug-DNA recognition: role of sequence-dependent DNA conformation
Araúzo-Bravo, M. J., & Sarai, A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm892 · Cited by 23
Laughlin, S., Wang, S., Kumar, A., Farahat, A. A., Boykin, D. W., & Wilson, W. D. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201406322 · Cited by 25
HIC1 interacts with and modulates the activity of STAT3
Lin, Y.-M., Wang, C.-M., Jeng, J., Leprince, D., & Shih, H. (2013) · Cell Cycle · doi:10.4161/cc.25365 · Cited by 26
Kim, H. G., Hwang, Y. P., Han, E. H., Choi, J. H., Kwon, K., Chung, Y., Jeong, M. H., Jeong, T. C., Kang, W., & Jeong, H. G. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.02.043 · Cited by 25
High performance transcription factor-DNA docking with GPU computing
Wu, J., Hong, B., Takeda, T., & Guo, J. (2012) · Proteome Science · doi:10.1186/1477-5956-10-s1-s17 · Cited by 23
“Owning to their roles in cancer development, transcription factors are potential drug targets for cancer therapy [2-4].”
BackgroundCardiac hormones for the treatment of cancer
Vesely, D. L. (2013) · Endocrine Related Cancer · doi:10.1530/erc-13-0054 · Cited by 25
Active IKKβ promotes the stability of GLI1 oncogene in diffuse large B-cell lymphoma
Agarwal, N. K., Kim, C. H., Kunkalla, K., Konno, H., Tjendra, Y., Kwon, D., Blonska, M., Kozloski, G. A., Moy, V. T., Verdun, R. E., et al. (2016) · Blood · doi:10.1182/blood-2015-07-658781 · Cited by 23
“This is of potential clinical significance, because they can be targets for therapeutic intervention.(41) One of these transcription factors isGLI1,which is constitutively active in several cancers.”
BackgroundYadav, A. K., Kumar, V. V., Bishop‐Bailey, D., & Jang, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020363 · Cited by 23
“It is thus suggested that targeted disruption of STAT-3 could be one potential approach to treat human cancers overexpressing STAT-3 [46].”
BackgroundWang, X., Ji, C., Zhang, H., Shan, Y., Ren, Y., Hu, Y., Shi, L., Guo, L., Zhu, W., Xia, Y., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.007664 · Cited by 23
“Because transcription is a critical control point in the production of many proteins, alterations of oncogenic or tumor suppressor proteins often involve dysregulated transcription (3).”
BackgroundSTAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.
Walker, S. R., Chaudhury, M., & Frank, D. A. (2011) · PubMed · Cited by 26
Dai, M., Feng, M., Ye, Y., Wu, X., Liu, D., Liao, M., & Cao, W. (2016) · Scientific Reports · doi:10.1038/srep19226 · Cited by 27
Ikegaki, N., & Shimada, H. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00312 · Cited by 27
Balachandran, P., Ibrahim, M. A., Zhang, J., Wang, M., Pasco, D. S., & Muhammad, I. (2021) · Molecules · doi:10.3390/molecules26030735 · Cited by 26
“In 2002, Darnell has pointed out the list of transcriptions factors such as Myc, Stat3, Wnt, ETS, E2F, Smad, Notch, and NF-κ B, which are overactive in certain types of cancers [17].”
Zhao, D., Zhang, J., Zhang, L., Wu, Q., Wang, Y., Zhang, W., Xiao, Y., Chen, J., & Zhan, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.014 · Cited by 24
Zhao, M., Kong, L., & Qu, H. (2014) · Scientific Reports · doi:10.1038/srep04176 · Cited by 24
Zhang, X., Li, X., Li, M., Ren, J., Yun, K., An, Y., Lin, L., & Zhang, H. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.044 · Cited by 26
Huang, T., Gonzales, C. B., Gu, F., Hsu, Y., Jadhav, R. R., Wang, C., Redding, S. W., Tseng, C.-E., Lee, C.-C., Thompson, I. M., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt112 · Cited by 27
Epidermal Growth Factor and Trail Interactions in Epithelial-Derived Cells
Gibson, S. B. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)67012-9 · Cited by 22
Coleman, D. R., Kaluarachchi, K., Ren, Z., Chen, X., & McMurray, J. S. (2007) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-007-9099-7 · Cited by 23
Programmable oligomers targeting 5′-GGGG-3′ in the minor groove of DNA and NF-κB binding inhibition
Chenoweth, D. M., Poposki, J. A., Marques, M. A., & Dervan, P. B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.10.051 · Cited by 22
Principled multi-omic analysis reveals gene regulatory mechanisms of phenotype variation
Hanson, C. R., Cairns, J., Wang, L., & Sinha, S. (2018) · Genome Research · doi:10.1101/gr.227066.117 · Cited by 32
“There have been new insights into how TFs may be regulated by small molecules and other mechanisms such as modulating protein-protein interactions (35) (36) (37) (38), and there is no doubt as to their significance in human diseases such as cancer (39) (36) (40) (41) (42).”
BackgroundKwon, H. S., Kim, D.-R., Yang, E. G., Park, Y. K., Ahn, H.-C., Min, S.-J., & Ahn, D.-R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.054 · Cited by 21
Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence
Kirti, A., Simnani, F. Z., Jena, S., Lenka, S. S., Kalalpitiya, C., Naser, S. S., Singh, D., Choudhury, A., Sahu, R. N., Yadav, A., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216990 · Cited by 22
Myc protein expression correlates with MYC amplification in small‐cell lung carcinoma
Hwang, D. H., Sun, H. H., Rodig, S. J., Hornick, J. L., & Sholl, L. M. (2014) · Histopathology · doi:10.1111/his.12622 · Cited by 22
“However, directly targeting Myc for therapy has proved difficult, owing to the lack of a well-established ligand-binding domain.(44,45) Attention has thus been turned to the targeting of upstream regulators or Myc co-activators.”
BackgroundSequence‐Selective DNA Recognition with Peptide–Bisbenzamidine Conjugates
Sánchez, M. I., Vázquez, O., Vázquez, M. E., & Mascarenas, J. L. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201300519 · Cited by 22
Ediriweera, M. K., Tennekoon, K. H., Adhikari, A., Samarakoon, S. R., Thabrew, I., & de Silva, E. D. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.05.047 · Cited by 21
Chiou, J., Chang, Y., Jan, Y., Tsai, H.-F., Yang, C., Huang, M.-S., Yu, Y., & Hsiao, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50874-x · Cited by 21
Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors
Cerulli, R. A., Shehaj, L., Tošić, I., Jiang, K. X., Wang, J., Frank, D. A., & Kritzer, J. A. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115542 · Cited by 21
Helix Mimetics as Inhibitors of the Interaction of the Estrogen Receptor with Coactivator Peptides
Becerril, J., & Hamilton, A. D. (2007) · Angewandte Chemie · doi:10.1002/ange.200700657 · Cited by 21
Targeting Transcription Factors for Cancer Prevention—the Case of Nrf2
Colburn, N. H., & Kensler, T. W. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0025 · Cited by 24
“Oncogenic factors frequently can be targeted directly (18), whereas tumor suppressors require indirect targeting or stabilization.”
BackgroundNatural and Synthetic Oligoarylamides: Privileged Structures for Medical Applications
Seedorf, T., Kirschning, A., & Solga, D. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202005086 · Cited by 22
Xing, J., Jia, Z., Xu, Y., Chen, M., Yang, Z., Chen, Y., & Han, Y. (2021) · Bioengineered · doi:10.1080/21655979.2021.1980644 · Cited by 20
Peng, J., Miller, M. A., Li, B. X., & Xiao, X. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00499 · Cited by 20
Kim, Y. R., Park, M. S., Eum, K., Kim, J., Lee, J. W., Bae, T., Lee, D. H., & Choi, J. W. (2015) · Oncotarget · doi:10.18632/oncotarget.5208 · Cited by 20
“Regulation of TFs may provide an economical method to change cellular physiology with minimum effort [9].”
Stasevich, T. J., Sato, Y., Nozaki, N., & Kimurâ, H. (2014) · Methods · doi:10.1016/j.ymeth.2014.08.002 · Cited by 19
Sathyaraj, G., Kiruthika, M., Weyhermüller, T., & Nair, B. U. (2012) · Dalton Transactions · doi:10.1039/c2dt30260h · Cited by 20
Stefanucci, A., Mosquera, J., Vázquez, E., Mascarenas, J. L., Novellino, E., & Mollica, A. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00363 · Cited by 20
Fucoidans: Anticancer Activity and Molecular Mechanisms of Action
Malyarenko, O. S., & Ermakova, S. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809816-5.00010-4 · Cited by 26
Zhang, L., Pan, H., Zhong, L., Wei, K., Yang, X. Y., Li, J., Shen, G.-F., & Zhang, Z. (2010) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2009.00869.x · Cited by 21
E2F4 Program Is Predictive of Progression and Intravesical Immunotherapy Efficacy in Bladder Cancer
Cheng, C., Varn, F. S., & Marsit, C. J. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0120 · Cited by 20
Kleine Moleküle als Transkriptionsmodulatoren
Arndt, H. (2006) · Angewandte Chemie · doi:10.1002/ange.200600285 · Cited by 20
DNA Vaccines Designed to Inhibit Tumor Growth by Suppression of Angiogenesis
Reisfeld, R. A., Niethammer, A. G., Luo, Y., & Xiang, R. (2004) · International Archives of Allergy and Immunology · doi:10.1159/000077009 · Cited by 20
Chromatin Mechanisms Driving Cancer
Gryder, B. E., Scacheri, P. C., Ried, T., & Khan, J. I. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a040956 · Cited by 20
Ren, F., Geng, Y., Minami, T., Qiu, Y., Feng, Y., Liu, C., Zhao, J., Wang, Y., Fan, X., Wang, Y., et al. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.05.031 · Cited by 19
“Many tumors are attributed to the constitutive STAT3 phosphorylation, which can be a consequence of either increased expression and activation of positive regulators or decreased activities of negative regulators including phosphatases [18,19].”
BackgroundZhang, C., Yang, L., Yang, X., Gao, Q., Qu, Y. D., & Wu, L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106541 · Cited by 20
Mandal, P. K., Ren, Z., Chen, X., Kaluarachchi, K. K., Liao, W. S. ‐., & McMurray, J. S. (2012) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-012-9313-0 · Cited by 19
“…is recruited to the pTyr residues on gp130 where Stat3 becomes phosphorylated at Tyr705 (pStat3) by the JAKs. pStat3 dimerizes via reciprocal pTyr-SH2 domain interactions, is translocated to the nucleus, and participates in the transcription of acute phase response genes (Levy and Darnell 2002).”
BackgroundMethodBonham, A. J., Wenta, N., Osslund, L. M., Prussin, A. J., Vinkemeier, U., & Reich, N. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1085 · Cited by 20
Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer
Haviland, R., Eschrich, S., Bloom, G., Ma, Y., Minton, S., Jove, R., & Cress, W. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024923 · Cited by 19
Shao, W., Hua-jiang, W., Qiao, J.-Y., Zhao, Y., Sun, Y.-M., Zhou, Y.-X., & Cheng, J. (2005) · Journal of Proteome Research · doi:10.1021/pr050053l · Cited by 19
Zhu, M., Liu, C.-C., & Cheng, C. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-504 · Cited by 20
“Aberrant expression or activation/inactivation of TFs has been implicated in human diseases [9], particularly, in a variety of different cancer types [10,11].”
BackgroundSzymanski, P. T., Kuppast, B., Ahmed, S. A., Khalifa, S. I., & Fahmy, H. T. Y. (2011) · Marine Drugs · doi:10.3390/md10010001 · Cited by 20
“Several studies demonstrated that inhibition of STAT-3 activation, as regards to both phosphorylation and expression, correlates with suppression of human malignant cells in experimental systems both in the in vitro and in vivo conditions [16,17,40].”
BackgroundSignal transducer and activator of transcription 3 regulation by novel binding partners
Matsuda, T., Muromoto, R., Sekine, Y., Togi, S., Kitai, Y., Kon, S., & Oritani, K. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i4.324 · Cited by 21
RegulatorTrail: a web service for the identification of key transcriptional regulators
Kehl, T., Schneider, L., Schmidt, F., Stöckel, D., Gerstner, N., Backes, C., Meese, E. U., Keller, A., Schulz, M. H., & Lenhof, H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx350 · Cited by 19
Kim, Y. H., Yoon, Y. J., Lee, Y., Kim, C., Lee, S., Choung, D. H., Han, D. C., & Kwon, B. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.025 · Cited by 19
Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3
Qi, X., Li, M., Zhang, X., Dai, X.-F., Cui, J. T., Li, D., Gu, Q., Lv, Z., & Li, J. (2020) · Molecules · doi:10.3390/molecules25102306 · Cited by 22
Ubiquitination in cancer stem cell: roles and targeted cancer therapy
Liu, L., Yin, S., Brobbey, C., & Gan, W. (2020) · STEMedicine · doi:10.37175/stemedicine.v1i3.37 · Cited by 20
Tosso, P. N., Kong, Y., Scher, L., Cummins, R., Schneider, J. A., Rahim, S., Holman, K. T., Toretsky, J. A., Wang, K., Üren, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501372p · Cited by 18
Spinsanti, P., Vita, T. D., Caruso, A., Melchiorri, D., Misasi, R., Caricasole, A., & Nicoletti, F. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05111.x · Cited by 21
Wei, J., Yang, Y., Li, Y., Mo, X., Guo, X., Zhang, X., Xu, X., Jiang, Z., & You, Q. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.021 · Cited by 22
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
Li, S., Vallet, S., Sacco, A., Roccaro, A. M., Lentzsch, S., & Podar, K. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1605354 · Cited by 19
“promoters; enhancers; and clustered enhancers, so-called superenhancers (SE)) and thereby prompt (as activators) or block (as repressors) the recruitment and activity of RNA polymerases [1,2].”
BackgroundInfluentialMay the Best Molecule Win: Competition ESI Mass Spectrometry
Laughlin, S., & Wilson, W. D. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024506 · Cited by 22
“Unfortunately, it has proved very difficult to target TFs and they are frequently referred to as “undruggable” [64,65].”
BackgroundVangala, R. K., Ravindran, V., Ghatge, M., Shanker, J., Arvind, P., Bindu, H., Shekar, M., & Rao, V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057193 · Cited by 17
“been identified as potential biomarkers [30].”
AbdulMajeed, A. A., & Farah, C. S. (2013) · Biomarkers in Cancer · doi:10.4137/bic.s12951 · Cited by 18
Fatima, R., Choudhury, S. R., Divya, T. R., Bhaduri, U., & Rao, M. R. S. (2019) · Non-coding RNA Research · doi:10.1016/j.ncrna.2019.08.001 · Cited by 16
Construction of a novel DNA decoy that inhibits the oncogenic β-catenin/T-cell factor pathway
Seki, Y., Yamamoto, H., Ngan, C. Y., Yasui, M., Tomita, N., Kitani, K., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura∥, N., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0388 · Cited by 18
“Although a TCF decoy was theoretically possible (28), it was not shown before the work we report here.”
Background
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.